Automate Your Wheel Strategy on RMD
With Tiblio's Option Bot, you can configure your own wheel strategy including RMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RMD
- Rev/Share 35.1352
- Book/Share 40.744
- PB 6.7285
- Debt/Equity 0.1478
- CurrentRatio 3.4398
- ROIC 0.195
- MktCap 40138940175.0
- FreeCF/Share 11.3246
- PFCF 24.1986
- PE 28.667
- Debt/Assets 0.1079
- DivYield 0.008
- ROE 0.2551
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RMD | CLSA | Hold | Outperform | -- | -- | Sept. 2, 2025 |
| Upgrade | RMD | RBC Capital Mkts | Sector Perform | Outperform | -- | $294 | July 15, 2025 |
| Initiation | RMD | Morgan Stanley | -- | Overweight | -- | -- | March 19, 2025 |
| Initiation | RMD | Goldman | -- | Buy | -- | -- | Jan. 16, 2025 |
| Initiation | RMD | Piper Sandler | -- | Neutral | -- | $252 | Jan. 10, 2025 |
| Initiation | RMD | Stifel | -- | Hold | -- | $250 | Dec. 13, 2024 |
| Initiation | RMD | Robert W. Baird | -- | Outperform | -- | $280 | Sept. 24, 2024 |
| Downgrade | RMD | Wolfe Research | Peer Perform | Underperform | -- | $180 | Sept. 18, 2024 |
News
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Negative
RMD's Mask and Device sales fuel growth, but macro headwinds and fierce competition continue to challenge its performance.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apnea (OSA) in the United States over the next three decades due to a variety of factors, including an aging population and increasing body mass index (BMI). The study estimates that by 2050, OSA will affect nearly 77 million U.S. adults, representing a relative1 increase of nearly 35% from 2020 and impacting …
Read More
ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive
For my first rating of ResMed, I'm calling a buy, agreeing with today's consensus from Wall St. and more confident than the quant system, which said hold. Key upside factors are new business acquisitions and FDA approvals, proven demand momentum so far, and revenue diversification along with strong profit margins in its peer group. RMD is a proven dividend grower over 10 years while also having an attractive balance sheet risk profile with a low D/E ratio.
Read More
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Top 50 High-Quality Dividend Stocks For August 2025
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Positive
My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated future return of at least 10%, with 10 of these also appearing potentially undervalued by my Free Cash Flow model. Top highlighted stocks like MKTX, RACE, RMD, MSCI, and TTC combine strong free cash flow growth, attractive valuations, and double-digit return estimates.
Read More
ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings
Published: August 01, 2025 by: Benzinga
Sentiment: Positive
Resmed Inc RMD reported better-than-expected earnings for the second quarter on Thursday.
Read More
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.
Read More
All You Need to Know About ResMed (RMD) Rating Upgrade to Buy
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Scoop Up These 4 GARP Stocks to Receive Handsome Returns
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. SFM, ADBE, GE and RMD are some such stocks.
Read More
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Top 15 High-Growth Dividend Stocks For June 2025
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in May, gaining 6.45% versus SPY's 6.28% and VIG's 3.61%. The list's year-to-date return is 6.07%, beating SPY every month in 2025, though still short of my 12% annualized target. The June 2025 Top 15 stocks offer a 1.34% average dividend yield with a 22.82% 5-year dividend growth rate and are 25% undervalued.
Read More
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) reported earnings 30 days ago. What's next for the stock?
Read More
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Top 15 High-Growth Dividend Stocks To Consider For May 2025
Published: May 02, 2025 by: Seeking Alpha
Sentiment: Positive
My Top 15 High-Growth Dividend stocks for April 2025 outperformed SPY and VIG, posting a 0.12% gain versus SPY's -0.87% and VIG's -1.53%. Year-to-date, the Top 15 list returned -0.36%, outperforming VIG's -2.46% and SPY's -5.40%, aiming for a long-term 12% return. The May 2025 Top 15 stocks offer a 1.33% average dividend yield with a 21.25% 5-year dividend growth rate and are 29% undervalued.
Read More
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea (OSA) from the comfort of an individual's home.
Read More
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
RMD, GEHC and MDT are expected to thrive as NVIDIA and other AI leaders' MedTech ventures accelerate digital adoption within the space.
Read More
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution
Published: March 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions.
Read More
Is it Worth Adding ResMed Stock to Your Portfolio Now?
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
Read More
My Top 15 High-Growth Dividend Stocks For March 2025
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Positive
The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear to be about 25% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.63% compound annual growth rate.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
About ResMed Inc. (RMD)
- IPO Date 1995-06-02
- Website https://www.resmed.com
- Industry Medical - Instruments & Supplies
- CEO Michael J. Farrell BE, MBA, SM
- Employees 9980